KRRO - Rasio kapitalisasi pasar marang pendapatan Korro Bio Inc.
Korro Bio, Inc. (KRRO) leverages the OPERA platform for precise RNA editing to create a unique therapeutic circuit. The price-to-sales multiple on the GURU.Markets chart reflects market expectations, where 152.80 determines the latest valuation metric. Flexibility is ensured through outsourced manufacturing, while stability is maintained by successfully raising capital to fund preclinical development stages.
Korro Bio, Inc. (KRRO) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Korro Bio, Inc.|KRRO - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal korrobio.com|KRRO - Utang perusahaan|Utang-utang marang kapitalisasi buku Korro Bio, Inc|KRRO - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Korro Bio|Rasio jangkoan perantara korrobio.com
- data bathi resik lan rasio valuasi:
KRRO - Bathi resik perusahaan|Bathi resik sing dikarepake Korro Bio, Inc.|KRRO - Pangali P/E|Rasio rega marang bathi mangsa ngarep korrobio.com|KRRO - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Korro Bio, Inc|KRRO - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Korro Bio|KRRO - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan korrobio.com|KRRO - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Korro Bio, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:KRRO Korro Bio Inc.
Finding a balance between capital preservation and growth potential requires an analysis of the ratio of asset market value to actual cash flows. For Korro Bio, Inc. (KRRO), which focuses on organic RNA editing research without external mergers, the market-to-revenue valuation reflects a premium for future technological breakthroughs, measuring the cost of each unit of current income to determine the fundamental sustainability of the business.
Pesaing Korro Bio, Inc.
TEM - Rega marang dodolan|Qiagen - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|Repligen Corp. - Multiplikator P/S|Koefisien rega marang pendapatan Avidity Corp RNA|CRISPR Therapeutics AG (CRSP) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx) - Multiplikator P/S|Kapitalisasi marang pendapatan Beam Therapeutics Inc (BEAM)|Kapitalisasi marang pendapatan SRPT (Sarepta Therapeutics Inc)|Koefisien rega marang pendapatan Twist Bioscience Corp|Rasio rega marang pendapatan 10x Genomics, Inc. TXG|Multiplikator P/S intelliatx.com NTLA|STOK - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan BLFS (BioLife Solutions Inc)|Wave Life Sciences Corp (WVE) - Rasio rega marang pendapatan|Maze Therapeutics Corp - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Sionna Therapeutics Inc|Rega marang dodolan primemedicine.com PRME|Multiplikator P/S TSHA|uniQure NV - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan MeiraGTx PLC MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc. - Multiplikator P/S|OCGN - Multiplikator P/S|PacBio (PACB) - Rasio rega marang pendapatan|Benitec Biopharma Inc (BNTC) - Multiplikator P/S|Rasio rega marang pendapatan Design Pharma|Rega marang dodolan Rocket Corp RCKT|Rasio rega marang pendapatan 4D Molecular Therapeutics (FDMT)|LXEO (lexeotx.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Editas Medicine EDIT|Rasio kapitalisasi pasar marang pendapatan SLN|PRQR - Rasio rega marang pendapatan|Rega marang dodolan Codexis, Inc.|SGMO (Sangamo Therapeutics) - Kapitalisasi marang pendapatan|Nautilus Bio - Rasio kapitalisasi pasar marang pendapatan|MGX (Metagenomi) - Multiplikator P/S|Rasio rega marang pendapatan DTIL|Multiplikator P/S GBIO|Koefisien rega marang pendapatan Boundless Bio Inc|Rasio rega marang pendapatan Exicure XCUR|Imunon Inc (IMNN) - Rega marang dodolan|PHIO: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (Mustang Bio, Inc.)|RNAZ: Multiplikator P/S|BNGO - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Applied DNA Sciences|Rasio kapitalisasi marang pendapatan BLUE (bluebirdbio.com)|Multiplikator P/S IPA|Kapitalisasi marang pendapatan Omega Therapeutics Inc OMGA|Singular Genomics Systems Inc - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Regulus (RGLS)|SYRS - Rasio rega marang pendapatan|TBIO - Multiplikator P/S|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology Inc. - Rasio kapitalisasi pasar marang pendapatan
